Abstract
Phospholipase A2 (PLA2) hydrolyses certain phospholipids of low density lipoproteins. PLA2-treated LDL is known to be rapidly cleared from plasma. A prototype plasma filter containing immobilizedCrotalus atrox PLA2 on agarose beads was developed. After a 90 min treatment with the extracorporeal device, plasma cholesterol concentration in cholesterol-fed NZW rabbits decreased by 32%. The decrease was dependent on the enzymatic activity in the plasma filter. The decrease in plasma cholesterol of hypercholesterolemic rabbits that were treated with control reactors (agarose beads only) was 5%. White and red blood cell counts and platelets remained unchanged during the treatment. Plasma cholesterol reduction (25–40%) was also obtained following intravenous injection of active PLA2 to modify plasma lipoproteins. PLA2 infusion created a radical change in biliary composition. Bile phospholipid composition was 90–95% lysophosphatidylcholine as compared with more than 95% before injection of active PLA2. Phospholipid and bile salts total mass increased by 10%. While biliary secretion rate of protein increased by 10%, biliary secretion rate of cholesterol remained unchanged. This technique is specific for lipoproteins, does not require any fluid replacement of sorbent regeneration, and offers a potential new approach for lowering serum cholesterol and LDL levels.
Similar content being viewed by others
References
B. M. RIFKING,JAMA 251 (1984) 351.
H. A. TYROLER, in “Hypercholesterolemia and atherosclerosis” (Churchill Livingstone, New York, 1987) p. 99.
J. L. GOLDSTEIN and M. S. BROWN,Ann. Rev. Biochem. 46 (1977) 897.
The Lovastatin Study Group III,JAMA 260 (1988) 359.
C. S. APSTEIN, D. B. ZILVERSMIT, R. S. LEES and P. K. GEORGE,Atherosclerosis 298 (1978) 34.
M. E. KING, J. L. BRESLOW and R. S. LEES,New England J. Med. 302 (1980) 1457.
H. MABUCHI, I. MICHISHITA, M. OONISHIet al. Atherosclerosis 68 (1987) 19.
W. STOFFEL and T. DEMANT,Proc. Natn. Acad. Sci. 78 (1980) 611.
Y. HACHIMORI, M. A. WELLS and D. J. HANAHAN,Biochem. 10 (1971) 4084.
G. R. BARLETT,J. Biol. Chem. 234 (1959) 466.
K. NILSSON and K. MOSBACH,Meth. Enzymol. 104 (1984) 56.
Pharmacia product report.
C. J.-P. MULLON, W. M. SALTZMAN and R. LANGER,Biotechnol. 6 (1988) 927.
W. NIEUWENHUIZEN, H. KUNZE and G. H. de HAAS,Meth. Enzymol. 321 (1974) 147.
S. D. TURLEY and J. M. DIETSCHY,J. Lipid Res. 19 (1978) 924.
L. A. BRICKER, II, J. WEIS and M. D. SIPERSTEINJ. Clin. Invest. 51 (1972) 197.
O. H. LOWRY, N. J. ROSEBROUGH, A. L. FARR and R. J. RANDALL,J. Biol. Chem. 193 (1951) 265.
R. LABEQUE, C. J.-P. MULLON, J.-P. M. FERREIRA, R. S. LEES and R. S. LANGER,Science, submitted.
C. J.-P. MULLON, R. LEES, H. D. CONLON, R. LABEQUE, C. TOSONE, A. MILLER and R. LANGER, in Proceedings of the American Institute of Chemical Engineers, San Francisco, 1989.
F. T. HATCH and R. S. LEES,Adv. Lipid Res. 6 (1968) 1.
M. ANGELICO, D. ALVARO, R. MASELLA, G. S. CORRADINI and A. CANTAFORA,Biochim. Biophys. Acta 905 (1987) 91.
S. ERLINGER, in “The liver: biology and pathobiology”, 2nd edn (Raven Press Ltd, New York, 1988) p. 643.
C. DIVE, R. A. NADALINI and J. P. VAERMAN,Eur. J. Clin. Invest. 4 (1974) 241.
A. J. DONOVAN, M. A. CHILD and A. S. MASTO,Surg. Gynecol. Obstet. 134 (1972) 89.
N. F. LARUSSO,Amer. J. Physiol. 247 (1984) G199.
M. M. FISHER, B. NAGY, H. GAZIN and B. J. UNDERDOWN,Proc. Natn. Acad. Sci. USA 76 (1978) 2008.
R. LANGER,Science 217 (1982) 261.
A. LAVIN, C. SUNG, A. KLIBANOV and R. LANGER, ibid.230 (1985) 543.
M. D. KLEIN and R. LANGER,Trends Biot. 4 (1986) 179.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Labeque, R., Clark, B.M., Ferreira, J. et al. Phospholipase A2-catalysed modification of plasma low density lipoproteins caused reduction of hypercholesterolemic rabbit plasma cholesterolin vivo . J Mater Sci: Mater Med 3, 5–9 (1992). https://doi.org/10.1007/BF00702937
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00702937